Trending Topic

Brain head human mental idea mind 3D illustration background
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cognitive impairment is the hallmark symptom of Alzheimer’s disease (AD); however, neuropsychiatric symptoms (NPS), including psychosis, agitation and mood disturbances, are common not only in AD but also in Parkinson’s disease, dementia with Lewy bodies, frontotemporal dementia and vascular dementia.1–5 Psychotic symptoms have been reported to be present in 12–74% of patients with AD, with […]

Ray Chaudhuri, EAN 2022: Update on opicapone for Parkinson’s disease

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 27th 2022

Opicapone has proved effective for the treatment of end-of-dose motor fluctuations in patients with Parkinson’s disease. Here, Prof. Ray Chaudhuri (King’s College Hospital, London, UK) discusses the effect of disabling fluctuations and dyskinesias on patient quality of life, efficacy and safety of opicapone, and the best way to incorporate this treatment into practice.

Questions:

  1. For people with Parkinson’s disease, the emergence of disabling fluctuations and dyskinesias can severely impact quality of life; how does this affect patients, and how is it currently managed? (00:21)
  2. What is currently known about the efficacy and safety of opicapone in treating Parkinson’s disease? (02:13)
  3. What are your findings in effect on quality of life and non-motor symptoms in this analysis of opicapone? (03:10)
  4. How could opicapone be incorporated into practice to best support people with Parkinson’s disease and motor fluctuations? (05:03)

The abstract titled ‘OCEAN Study in Parkinson’s: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone’ (Abstract #EPO-377) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.

Disclosures: Ray Chaudhuri has participated in advisory boards for AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma and Medtronic; received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial, Kyowa Kirin, SK Pharma; investigator initiated grants from Bial, Britannia Pharmaceuticals, AbbVie, UCB, GKC; Aacdemic grants from EU Horizon 2020, Parkinson’s UK, NIHR, Parkinson’s Foundation, Wellcome Trust; Kirby Laing Foundation, MRC; royalties or licenses from Oxford (book), Cambridge publishers (book), MAPI institute (KPPS, PDSS 2); and payment for expert testimony from GMC.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.

Filmed as a highlight of EAN 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup